QF0301B is an α1-adrenergic receptor antagonist with additional blocking activity at α2-adrenergic, 5-HT2A, and histamine H1 receptors; it is used in cardiovascular research to study adrenergic, serotonergic, and histaminergic pathways; it produces a pronounced and prolonged decrease in mean arterial blood pressure and bradycardia in vivo; it markedly inhibits the hypertensive effect of noradrenaline; it competitively antagonizes the contractile effects of 5-HT and histamine in various isolated tissue preparations.